CHOosing Interventions that are Cost Effective (WHO-CHOICE)

EMR B: Cost effectiveness results for Blindness

This Table provides summary results of the total population-level costs, effects and cost-effectiveness for the selected WHO sub-region and risk factor / disease for the year 2000.

KEY
I$ - International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most cost-effective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most cost-effective strategies.


Interventions:Codes_and_Descriptions Coverage Cost per year (I$, millions) per one million_population [i.e. cost per capita] % Program costs % Patient costs DALYs averted per year per one million_population Average Cost per DALY averted Incremental Cost per DALY averted
CTR-1: Intra-capsular Cataract extraction using aphakic glasses (50%) 50% 0.81 71% 29% 2,604 310 Dominated
CTR-2: Intra-capsular Cataract extraction using aphakic glasses (80%) 80% 0.96 61% 39% 4,199 230 Dominated
CTR-3: Intra-capsular Cataract extraction using aphakic glasses (95%) 95% 1.09 59% 41% 5,005 219 Dominated
CTR-4: Extra-capsular Cataract extraction with posterior chamber lens implant (50%) 50% 0.80 71% 29% 4,784 167 Dominated
CTR-5: Extra-capsular Cataract extraction with posterior chamber lens implant (80%) 80% 0.95 61% 39% 7,765 123 Dominated
CTR-6: Extra-capsular Cataract extraction with posterior chamber lens implant (95%) 95% 1.08 59% 41% 9,288 116 116
TRC-1: Mass treatment of trachoma with tetracycline ointment (at 50%, 80% and 95% coverage) ALL 1.45 70% 30% 7 211,731 Dominated
TRC-2: Mass treatment of trachoma with azithromycin (at 50%, 80% and 95% coverage) ALL 2.25 44% 56% 35 65,022 Dominated
TRC-3: Targeted treatment of trachoma with azithromycin (at 50%, 80% and 95% coverage) ALL 3.34 29% 71% 24 136,946 Dominated
TRC-4: Targeted treatment of trachoma with surgery (at 80% of current prevalence) 80% 0.05 60% 40% 665 78 78
TRC-5: Combination (TRC1 + TRC4) 1.50 70% 30% 671 2,234 Dominated
TRC-6: Combination (TRC2+ TRC4) 2.30 44% 56% 699 3,289 65,022
TRC-7: Combination (TRC3 + TRC4) 3.39 30% 70% 689 4,926 Dominated
Share